What IMI Consulting does

IMI Consulting GmbH is a privately held management consulting firm founded in 1991 and headquartered in Wedemark near Hanover, Germany. The firm operates exclusively in the life sciences sector, providing strategic advisory services to pharmaceutical, biotechnology, MedTech, and diagnostics companies. Its service portfolio spans strategy development (market analyses, pipeline and segment planning), transaction support (business development and mergers & acquisitions), and capital raising. IMI serves both large international pharmaceutical conglomerates and mid-sized life sciences companies, with a secondary focus on venture capital and private equity investors active in the sector, and claims coverage of nearly all decision-makers in Europe, North America, and Japan/APAC.

The firm delivers engagements through a lean core team of 1-10 people combined with a network of over 150 associate partners, applying proprietary methodologies for forecasting, financial and market analysis, business intelligence, deal valuation, benchmarking, and negotiations. Its geographic footprint spans Europe, North America, and Asia-Pacific, and its therapeutic coverage extends from small molecules to biologicals, MedTech, diagnostics, OTCs, and nutritionals. IMI has completed or influenced over 60 transactions across biotech, pharma, and diagnostics, with disclosed outcomes including a $2.0 billion CNS business built through market creation for a European conglomerate, a 31-country APAC immuno-oncology transaction creating a Swiss joint venture with a 25% equity stake, a 138 million CHF GI company sale, and a 7-country European alliance with $1.1 billion NPV.

IMI generates revenue through project-based professional consulting fees under a sales-led, enterprise field-sales motion targeting senior decision-makers directly. The firm is led by Founder Mariana Brea-Krueger, whose prior executive tenure includes Rhône-Poulenc Rorer (Sanofi), International Venture Business Europe, Schering-Plough, Abbott International, and McKinsey, alongside Managing Director Winfried Krueger. Customer acquisition relies on direct engagement, a LinkedIn presence, and industry conference publications and presentations rather than paid digital channels. No external institutional investors, parent companies, subsidiaries, or funding rounds are disclosed, and the firm is GDPR-compliant under a Privacy Policy effective September 19, 2018.

Name

IMI Consulting

Legal name

IMI Consulting GmbH

Website

https://imiconsulting.com

Company type

Private

Founded year

1991

Operating status

Operating

Headcount range

1–10 employees

Short description

IMI Consulting GmbH, founded in 1991 and headquartered near Hanover, Germany, is a life sciences management consulting firm providing strategy, M&A, and capital raising advisory to pharmaceutical, biotech, MedTech, and diagnostics companies across Europe, North America, and Asia-Pacific.

Ownership category

akta.pro rank

Product category

Life Sciences Management Consulting

NAICS

Management Consulting Services (54161), Other Scientific and Technical Consulting Services (54169)

SIC

Services-Management Consulting Services (8742), Services-Engineering, Accounting, Research, Management (8700)

akta.pro primary industry

Industry-Specialist / Sector-Focused M&A Advisory (FSAEAGAJ)

akta.pro secondary industry

M&A Advisory (Buy-side/Sell-side) (BPAHADAC)

Keywords

• Life sciences consulting
• Strategic advisory services
• Mergers acquisitions advisory
• Business development consulting
• Pharma biotech consulting

Headquarters

HQ city

Hanover

HQ country

Germany

HQ region

Europe

Offices2 records

Markets served

GTM type

B2B

Offering type

Services

Cost components

Personnel, Operations, Marketing or Sales, Others

Revenue model

1. Management Consulting Services: IMI Consulting generates revenue through professional consulting engagements providing strategic advisory services, transaction support (M&A, business development), and capital raising assistance to life sciences companies. The firm serves international corporations as well as mid-sized pharma, biotech, medtech, and diagnostics companies, offering customized solutions tailored to client needs.

Go-to-market motion1 record

Distribution channels1 record

Marketing channels2 records

Core offering

IMI Consulting is a life sciences management consulting firm that delivers customized strategic advisory and transaction support to pharmaceutical, biotechnology, MedTech, and diagnostics companies. Its services span strategy development and implementation (market knowledge, pipeline and market-segment analyses, strategic planning), business development and licensing, mergers and acquisitions support, and capital raising. Engagements are staffed via a network of over 150 associate partners providing expertise across most therapeutic indications and geographies including Europe, North America, and Japan/APAC.

Product overview

IMI Consulting is a life-sciences management consulting firm providing advisory services to pharmaceutical, biotechnology, MedTech, and diagnostics companies. Services include strategy development and implementation (market analyses, pipeline and market-segment analyses, strategy plans), transaction support (business development, mergers and acquisitions), capital raising, and global marketing. The firm draws on a network of over 150 associate partners to deliver customized consulting across therapeutic indications and geographies (Europe, North America, APAC). The company also publishes conference presentations and research reports as part of its knowledge-distribution offering, but these are informational publications rather than standalone software products.

Differentiator

Problem solved

Functional benefit

Products and services

• Strategy Development and Implementation Customized advisory engagements covering market knowledge, development of new pathways for competitiveness, pipeline and market-segment analyses, strategy plans, and strategy implementation for life sciences companies. Serves both international pharmaceutical conglomerates and mid-sized pharma, biotech, MedTech, and diagnostics companies.
• Business Development and Licensing Support Advisory support for business development and licensing transactions in the life sciences sector, including deal-making support, alliance negotiations, and partnership structuring for pharma, biotech, MedTech, and diagnostics clients.
• Mergers and Acquisitions Support M&A advisory services for life sciences clients, including deal valuation, due diligence, negotiation, and execution support for mergers, acquisitions, divestitures, and joint ventures in biotech, pharma, and diagnostics.
• Capital Raising Advisory Advisory support to life sciences companies seeking to raise capital, including financing strategy and assistance with financing transactions for innovation and growth at pharma, biotech, MedTech, and diagnostics clients.

Quantifiable outcome

• Built a 2.0 Billion USD CNS business via market creation for a European conglomerate
• +5 more outcomes

Segments3 records

Ideal customer profiles3 records

Technology focussed No

API detail

Has API

No

API docs

API detail

Core technology

AI maturity

App detail

Scale indicators5 records

Recent moves3 records

Expansion highlights4 records

Direct peers

• PharmaVentures: Specialized pharma M&A advisory and transaction-support firm assisting biotech and pharma clients with licensing, partnerships, and deal-making — directly comparable to IMI's business-development and M&A practice.
• Catenion: Boutique life-sciences strategy consulting firm focused on pharma/biotech R&D portfolio strategy, valuation, and transaction support — comparable in scale, niche focus, and service mix to IMI.
• Health Advances: Boutique strategy consulting firm exclusively serving life-sciences clients on commercial strategy, M&A due diligence, and transaction support — closely comparable to IMI in size, focus, and service offering.
• Putnam Associates: Strategy consulting firm focused exclusively on life sciences, advising biopharma clients on commercial strategy, due diligence, and asset valuation — comparable in vertical specialization and engagement type to IMI.
• Simon-Kucher & Partners: Global consulting firm with a strong life-sciences vertical providing strategy, commercial, and transaction advisory; comparable to IMI in serving mid-sized and large pharma/biotech clients on growth and deal strategy.
• L.E.K. Consulting: Global strategy consulting firm with a deep, dedicated life-sciences practice advising pharma, biotech, and medtech clients on strategy, M&A, and commercial due diligence — directly comparable to IMI's core service mix.
• ZS Associates: Major life-sciences-focused consulting firm serving pharma, biotech, and medtech clients on strategy, commercialization, and transactions; overlaps heavily with IMI's therapeutic and client coverage.
• Deallus Consulting: Life-sciences-focused strategy consultancy advising pharma and biotech clients on competitive strategy, asset valuation, and commercial due diligence — closely comparable to IMI's therapeutic-area and deal-support work.

Broad incumbents

• McKinsey & Company (Pharma & Medical Products practice): Global top-tier strategy consultancy with a major pharma/biotech/medtech practice — competes with IMI for high-end life-sciences strategy and transaction engagements and is where IMI's founder previously worked.
• Charles River Associates: Established global consulting firm with a life-sciences practice offering strategy, economic, and transaction advisory — comparable to IMI's strategic and M&A advisory work but with much broader scale and service range.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

• LinkedInde.linkedin.com/company/imi-consulting-gmbh
• Xx.com/imi_consulting

Compliance1 record

Revenue estimate

Valuation estimate

Number of profiles

Profiles2 records

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IMI Consulting